Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. (March 2016)

• Record Type: Journal Article
• Authors: Muzaffar, Mahvish; Jia, Jingquan; Liles, Darla; Naveed, Musharraf; Kumari, Anita
• Is Part Of: American journal of therapeutics. Volume 23:Number 2(2016)
• Publication Date: 2016-03
• Subjects: T-DM1 -- ado-trastuzumab emtansine -- pancreatitis -- metastatic breast cancer; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.58
• DOI: 10.1097/MJT.0000000000000179
• Languages: English
• ISSNs: 1075-2765

Abstract

Abstract : Ado-trastuzumab emtansine (T-DM1) is a novel antibody–drug conjugate with current FDA recommendation for second-line treatment of HER-2-positive metastatic breast cancer. It is a human epidermal growth factor receptor (HER-2)-targeted antibody–drug conjugate composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Ado-trastuzumab emtansine improved both progression-free and overall survival as reported in EMILIA trial. With ongoing clinical trials in adjuvant and first-line setting for HER-2-positive early and metastatic breast cancer, it is prudent to recognize, report, and treat any adverse events related to T-DM1. We report a case of acute pancreatitis in a 54-year-old woman with metastatic breast cancer after she received her first dose of ado-trastuzumab emtansine. To the best of our knowledge, this is the first reported case of acute pancreatitis with probable association with ado-trastuzumab emtansine.